Nasdaq:US$17.66 (-0.22) | HKEX:HK$27.20 (-1.00) | AIM:£2.87 (-0.03)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
公告及新闻稿, 监管通知 | 2017-08-07

Directors’ Share Dealing

London: Monday, August 7, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:-

(a) Mr Simon To, Executive Director and Chairman, through Dynamic Drive Limited, a person closely associated (“PCA”) with Mr To, purchased a total of 1,748 American Depositary Shares of the Company (“ADSs”, each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med (“Ordinary Share”)) on August 2, 2017 at a price of US$22.97 per ADS. Dynamic Drive Limited is controlled by the trustee of Dynamic Drive Trust (the “DDT”) which has been established for the benefit of Mr To’s family members, of which Mr To is the settlor;

(b) Mr To through Wencheng Capital Limited (“WCL”), a PCA with Mr To, purchased a total of 1,826 ADSs between August 2 and August 3, 2017 at an average price of US$22.93 per ADS. WCL is controlled by the trustee of Wencheng Trust (“WT”) which has been established for the benefit of Mr To’s family member, of which Mr To is the settlor;

(c) Mr Paul Carter, Independent Non-executive Director, purchased a total of 724 Ordinary Shares at a price of GBP34.25 per share on August 2, 2017;

(d) Dr Dan Eldar, Non-executive Director, purchased a total of 1,900 Ordinary Shares at an average price of GBP34.93 per share on August 2, 2017;

(e) Dr Karen Ferrante, Independent Non-executive Director, purchased a total of 3,245 ADSs at an average price of US$22.94 per ADS on August 2, 2017; and

(f) Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 7,712 ADSs and 10,000 Ordinary Shares at an average price of US$23.29 per ADS and GBP34.75 per share respectively between August 3 and August 4, 2017.

Following the above purchases, (i) Mr To is interested in 110,401 ADSs (in DDT and WT of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.39% of the current issued share capital of Chi-Med; (ii) Mr Carter is interested in 3,524 Ordinary Shares, representing approximately 0.006% of the current issued share capital of Chi-Med; (iii) Dr Eldar is interested in 1,900 Ordinary Shares and 6,225 ADSs, representing approximately 0.008% of the current issued share capital of Chi-Med; (iv) Dr Ferrante is interested in 5,785 ADSs, representing approximately 0.005% of the current issued share capital of Chi-Med; and (v) Ms Shih is interested in 83,856 ADSs and 70,000 Ordinary Shares, representing approximately 0.18% of the current issued share capital of Chi-Med.

Please download the full announcement for the notifications provided in accordance with the requirements of the EU Market Abuse Regulation.